ZUMA-8 Trial: Advancing CAR T-Cell Therapy with Brexucabtagene Autoleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia
The ZUMA-8 phase 1 study evaluates the safety and efficacy of brexucabtagene autoleucel, a CD19-directed CAR T-cell therapy, in relapsed/refractory CLL, showing promising response rates and manageable safety profiles, especially in patients with low tumor burden.